Dennis M. Mulroy Net Worth

The estimated Net Worth of Dennis Mulroy is at least $591 millier dollars as of 22 May 2024. Mr Mulroy owns over 1,500 units of AnaptysBio Inc stock worth over $34,318 and over the last 11 years he sold ANAB stock worth over $108,006. In addition, he makes $448,807 as Chief Financial Officer at AnaptysBio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Mulroy ANAB stock SEC Form 4 insiders trading

Mr has made over 5 trades of the AnaptysBio Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 1,500 units of ANAB stock worth $35,580 on 22 May 2024.

The largest trade he's ever made was exercising 6,000 units of AnaptysBio Inc stock on 14 September 2023 worth over $213,600. On average, Mr trades about 286 units every 46 days since 2014. As of 22 May 2024 he still owns at least 964 units of AnaptysBio Inc stock.

You can see the complete history of Mr Mulroy stock trades at the bottom of the page.

Mr. Dennis M. Mulroy biography

Dennis M. Mulroy is the Chief Financial Officer at AnaptysBio Inc.

What is the salary of Mr Mulroy?

As the Chief Financial Officer of AnaptysBio Inc, the total compensation of Mr Mulroy at AnaptysBio Inc is $448,807. There are 3 executives at AnaptysBio Inc getting paid more, with Hamza Suria having the highest compensation of $7,875,190.

How old is Mr Mulroy?

Mr Mulroy is 66, he's been the Chief Financial Officer of AnaptysBio Inc since . There are 3 older and 11 younger executives at AnaptysBio Inc. The oldest executive at AnaptysBio Inc is Hollings Renton, 73, who is the Lead Independent Director.

What's Mr Mulroy's mailing address?

Dennis's mailing address filed with the SEC is 11750 Sorrento Valley Rd #250, San Diego, CA 92121, USA.

Insiders trading at AnaptysBio Inc

Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1 et James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.

What does AnaptysBio Inc do?

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c

Complete history of Mr Mulroy stock trades at AnaptysBio Inc et La Jolla Pharmaceutical Co

AnaptysBio Inc executives and stock owners

AnaptysBio Inc executives and other stock owners filed with the SEC include:

• Hamza Suria,
  President, Chief Executive Officer, Director
• Eric Loumeau,
  Chief Operating Officer, General Counsel
• Hamza Suria,
  Pres, CEO & Director
• Dennis M. Mulroy,
  Chief Financial Officer
• Dr. Paul F. Lizzul,
  Chief Medical Officer
• James Topper,
  Independent Chairman of the Board
• Dennis Fenton,
  Independent Director
• Hollings Renton,
  Lead Independent Director
• J. Anthony Ware,
  Independent Director
• John Schmid,
  Independent Director
• Laura Hamill,
  Independent Director
• Paul Lizzul,
  Chief Medical Officer
• Dennis Mulroy,
  Chief Financial Officer
• Eric J. Loumeau,
  COO & Gen. Counsel
• David McKeon,
  VP & Controller
• Dr. Margaret Marino,
  Sr. VP of Project Management
• Beth Mueller,
  Sr. VP of HR
• Nicholas Lydon,
  Director
• Carol Giltner Gallagher,
  Director
• Matthew Moyle,
  Chief Scientific Officer
• James A Schoeneck,
  Director
• Dominic Piscitelli,
  Chief Financial Officer
• Marco Londei,
  Chief Medical Officer
• Healthcare Vii, L.P.Frazier...,
  
• Healthcare V, Lpfhm V, Lpfh...,
  
• Holdings A/S Novo,
  10% owner
• Ventures Vii L Pavalon Vent...,
  
• John A Orwin,
  
• Magda Marquet,
  
• Rita Jain,
  
• Capital, Llcnodelman Oleg E...,
  
• Capital, Llc Eco R1,
  10% owner
• Daniel Faga,
  CEO